• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The Evidence Base for Polypharmacy in ADHD

The Evidence Base for Polypharmacy in ADHD

March 24, 2022
Pavan Madan, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Pavan Madan, MD. Dr. Madan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Baker M et al, J Child Adolesc Psychopharmacol 2021;31(3):148–163


TYPE of Study: Literature review


Psychotropic polypharmacy is increasingly the norm in clinical practice. We use it to address persistent symptoms or to target comorbid conditions, though we do so at the risk of increased side effects, more drug interactions, and worsened patient compliance. This review examines the evidence base for polypharmacy in the treatment of ADHD in children and adolescents.


The authors’ literature search found 39 studies and 17 randomized controlled trials (RCTs), a “relatively limited evidence base … to support a practice that occurred in 20% of outpatient visits in 2007 and is likely higher today.”


Nearly all trials included a stimulant. The most common additions were alpha-agonists, followed by risperidone and atomoxetine.


Sixteen of the 37 studies combined a stimulant and an alpha-agonist. RCT data showed that for stimulant partial responders, the combination of stimulant and alpha-agonist was superior to alpha-agonist alone in reducing residual ADHD symptoms, and superior to stimulant alone if there was a history of partial response to stimulant monotherapy, with an effect size of about 0.4. Combination treatment was associated with bradycardia, sedation, somnolence, and hypotension.


For ADHD with comorbid aggression and disruptive behavior, RCT data found that stimulants alone had a large effect size. Combination treatment with divalproex or risperidone did improve response beyond stimulant monotherapy, with the greatest support for risperidone; however, there was a price to pay. Despite the short study durations and the low dosages of risperidone (<2 mg/day) in all the studies, significant prolactin elevations and weight gain were seen.


One RCT of atomoxetine found no evidence of improvement with added MPH, with the suggestion that “optimizing dose and allowing adequate duration for response is favorable to adding medications.”


For management of comorbid anxiety, depression, and disruptive mood dysregulation disorder, data from four RCTs of SSRIs with stimulants showed this very common combination, while safe, had minimal benefit for anxiety and mood comorbidities.


The authors conclude the data support existing guidelines to start with stimulant monotherapy for ADHD. Still, antipsychotics are worth considering, despite their side effects, when aggression is severe or persistent. The authors recommend using measurement-based care to determine if the benefit of an added medication is worth the risk.


CCPR’s Take: Combination treatment for ADHD may be beneficial, though it comes at the cost of more side effects. Adding an alpha-agonist is helpful in partial responders to stimulants, and, in line with clinical lore, adding risperidone can be helpful for aggression. Remember that side effects can differ based on pubertal ­status.

Child Psychiatry
KEYWORDS adhd aggression central-alpha-agonists combined-pharmacotherapy divalproex polypharmacy risperidone stimulants
    Pavan Madan, MD.

    Methylphenidate Improves Mood and Boredom in Children with ADHD

    More from this author
    www.thecarlatreport.com
    Issue Date: March 24, 2022
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - ADHD in Children and Adolescents, CCPR, April/May/June 2022
    Note From the Editor-in-Chief
    The Evidence Base for Polypharmacy in ADHD
    Methylphenidate Improves Mood and Boredom in Children with ADHD
    Talking with Parents About Stimulant Treatment
    Treating Anxiety Disorders in Children: The New AACAP Clinical Practice Guideline
    Practical Issues with Prescribing ADHD Meds
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2432683359.jpg
      Child Psychiatry

      Hidden Dangers: The Fentanyl Crisis and Teen Overdose Prevention

      The Fentanyl overdose crisis is now one of the leading causes of death among adolescents, and it is happening in every corner of the country. Stay with us as we talk about the...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.